ELOX Eloxx Pharmaceuticals Inc

As filed with the Securities and Exchange Commission on January 24, 2024

 

Registration No. 333-            

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

Under

The Securities Act of 1933

 

 

Eloxx Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

  

 

Delaware	84-1368850
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

 

480 Arsenal Way

Watertown, Massachusetts 02472

(781) 577-5300

(Address, including zip code and telephone number, including area code, of Registrant’s principal executive offices)

 

ELOXX PHARMACEUTICALS, INC. 2018 EQUITY INCENTIVE PLAN

(Full title of the plan)

 

Sumit Aggarwal

Chief Executive Officer

Eloxx Pharmaceuticals, Inc.

480 Arsenal Way

Watertown, Massachusetts 02472

(Name and address of agent for service)

 

(914) 207-2300

(Telephone number, including area code, of agent for service)

 

Copies to:

 

Peter N. Handrinos, Esq.

Wesley C. Holmes, Esq.

Ellen Smiley, Esq.

Latham & Watkins LLP

200 Clarendon Street, 27^th Floor

Boston, MA 02116

(617) 948-6000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

  

 

 

EXPLANATORY NOTE

 

This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 157,170 shares (the “Additional Shares”) of common stock, par value $0.01 per share (the “Common Stock”), of Eloxx Pharmaceuticals, Inc. (the “Registrant”) issuable under the Registrant’s 2018 Equity Incentive Plan (the “2018 Plan”) pursuant to the provision of the 2018 Plan which provides for an annual automatic increase in the number of shares of Common Stock reserved for issuance under the 2018 Plan.

 

The Additional Shares are securities of the same class as other securities for which prior registration statements of the Registrant on Form S-8 were previously filed with the Commission on March 31, 2023 (File No. 333-271035), March 12, 2021 (File No. 333-254201), March 6, 2020 (File No. 333-236952), May 11, 2018 (File No. 333-224860) and January 10, 2018 (File No. 333-222499).

 

Pursuant to General Instruction E of Form S-8, the contents of the above-referenced prior registration statements are incorporated into this Registration Statement by reference to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein or therein.

 

Item 8. Exhibits.

 

Exhibit Number		Exhibit Description		Form		File No.		Exhibit Number		Filing Date	Filed Herewith
4.1		Amended and Restated Certificate of Incorporation of Senesco Technologies, Inc. filed with the State of Delaware on January 22, 2007		10-Q		001-31326		3.1		2/14/2007
4.2		Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Senesco Technologies, Inc. filed with the State of Delaware on December 13, 2007		10-Q		001-31326		3.1		2/14/2008
4.3		Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Senesco Technologies, Inc. filed with the State of Delaware on September 22, 2009		10-K		001-31326		3.3		9/28/2009

 

 

Exhibit Number		Exhibit Description		Form		File No.		Exhibit Number		Filing Date	Filed Herewith
4.4		Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Senesco Technologies, Inc. filed with the State of Delaware on May 25, 2010		8-K		001-31326		3.1		5/28/2010
4.5		Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Senesco Technologies, Inc. filed with the State of Delaware on December 22, 2011		10-Q		001-31326		3.1		2/14/2012
4.6		Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Senesco Technologies, Inc. filed with the State of Delaware on April 1, 2013		10-Q		001-31326		3.1		5/15/2013
4.7		Certificate of Amendment to the Registrant’s Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on October 16, 2013		8-K		001-31326		3.1		10/21/2013
4.8		Certificate of Amendment to the Registrant’s Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on September 29, 2014		8-K		001-31326		3.1		10/3/2014
4.9		Certificate of Amendment to the Registrant’s Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on December 19, 2017		8-K		001-31326		3.1		12/22/2017
4.10		Certificate of Amendment to the Registrant’s Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on December 19, 2017		8-K		001-31326		3.2		12/22/2017
4.11		Certificate of Amendment to Amended and Restated Certificate of Incorporation of Eloxx Pharmaceuticals, Inc., as filed with the Secretary of State of the State of Delaware on December 1, 2022		8-K		001-31326		3.1		12/1/2022
4.12		Amended and Restated Bylaws		8-K		001-31326		3.2		12/27/17

 

 

Exhibit Number		Exhibit Description		Form		File No.		Exhibit Number		Filing Date	Filed Herewith
4.1		Specimen of Common Stock Certificate		10-K		001-31326		4.1		3/16/2018
5.1		Opinion of Latham & Watkins LLP									*
23.1		Consent of Baker Tilly US, LLP									*
23.2		Consent of Latham & Watkins LLP (included in Exhibit 5.1).									*
24.1		Power of Attorney (included on signature page)									*
99.1		Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan		8-K		001-31326		10.1		3/30/2018
99.2		Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan		8-K		001-31326		10.2		3/30/2018
99.3		Israeli Sub-Plan under the Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan		8-K		001-31326		10.3		3/30/2018
99.4		Form of Israeli Stock Option Grant Package under the Israeli Sub-Plan under the Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan		8-K		001-31326		10.4		3/30/2018
99.5		Form of Restricted Stock Unit Grant Notice for non-Israeli employees		S-8		333-224860		99.5		5/11/2108
99.6		Form of Restricted Stock Unit Grant Notice for Israeli employees		10-Q		001-31326		10.6		8/10/2018
107.1		Filing Fee Table									*

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, State of Massachusetts, on this 24^th day of January 2024.

 

	ELOXX PHARMACEUTICALS, INC.
	By	/s/ Sumit Aggarwal
	Name	Sumit Aggarwal
	Title	Chief Executive Officer

 

POWER OF ATTORNEY

 

We, the undersigned officers and directors of Eloxx Pharmaceuticals, Inc., hereby severally constitute and appoint Sumit Aggarwal and Daniel Geffken, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities held on the dates indicated.

 

Signature		Title		Date
/s/ Sumit Aggarwal		Chief Executive Officer and Director (Principal Executive Officer)		January 24, 2024
Sumit Aggarwal
/s/ Daniel Geffken		Interim Chief Financial Officer (Principal Financial and Accounting Officer)		January 24, 2024
Daniel Geffken
/s/ Steven D. Rubin		Director		January 24, 2024
Steven D. Rubin
/s/ Lindsay Androski		Director		January 24, 2024
Lindsay Androski
/s/ Alan Walts, Ph.D.		Director		January 24, 2024
Alan Walts, Ph.D.

 

 

 

Exhibit 5.1

 

	200 Clarendon Street
	Boston, Massachusetts 02116
	Tel: +1.617.948.6000 Fax: +1.617.948.6001
	www.lw.com
	FIRM / AFFILIATE OFFICES
	Austin	Milan
	Beijing	Munich
	Boston	New York
	Brussels	Orange County
	Century City	Paris
	Chicago	Riyadh
January 24, 2024	Dubai	San Diego
	Düsseldorf	San Francisco
	Frankfurt	Seoul
	Hamburg	Silicon Valley
	Hong Kong	Singapore
	Houston	Tel Aviv
Eloxx Pharmaceuticals, Inc.	London	Tokyo
480 Arsenal Way, Suite 130	Los Angeles	Washington, D.C.
Watertown, Massachusetts 02451	Madrid

 

Re:

Registration Statement on Form S-8

 

To the addressee set forth above:

 

We have acted as special counsel to Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing by the Company on the date hereof with the Securities and Exchange Commission (the “Commission”) of a Registration Statement (the “Registration Statement”) on Form S-8 under the Securities Act of 1933, as amended (the “Act”), relating to the issuance of up to 157,170 shares (the “Shares”) of common stock of the Company, par value $0.01 per share (the “Common Stock”), which may be issued pursuant to the Company’s 2018 Equity Incentive Plan (the “2018 Plan”). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or prospectus forming a part thereof, other than as expressly stated herein with respect to the issuance of the Shares.

 

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware, as amended (the “DGCL”), and we express no opinion with respect to any other laws.

 

Subject to the foregoing and the other matters set forth herein, it is our opinion that as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers and have been issued by the Company for legal consideration in excess of par value in the circumstances contemplated by the 2018 Plan, assuming that the individual issuances, grants or awards under the 2018 Plan are duly authorized by all necessary corporate action and duly issued, granted or awarded and exercised in accordance with the requirements of law and the 2018 Plan (and the agreements duly adopted thereunder and in accordance therewith), the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and such Shares will be validly issued, fully paid and non-assessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

 

 

January 24, 2024

Page 2

 

 

 

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

 

	Sincerely,
	/s/ Latham & Watkins LLP

 

 

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 of our report dated March 31, 2023, relating to the consolidated financial statements of Eloxx Pharmaceuticals, Inc. which appears in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. Our report includes an explanatory paragraph relating to the Company's ability to continue as a going concern.

 

/s/ BAKER TILLY US, LLP

 

Tewksbury, Massachusetts

January 24, 2024

 

 

 

Exhibit 107.1

 

CALCULATION OF FILING FEE TABLES

 

FORM S-8

(Form Type)

 

Eloxx Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1—Newly Registered Securities

 

Security Type	Security Class  Title	Fee Calculation Rule	Amount to be Registered (1)	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
Equity	Common Stock, $0.01 par value per share	Rule 457(c) and Rule 457(h)	157,170(2)	$1.11(3)	$174,458.70	$ 147.60 per million dollars	$25.76
Total Offering Amounts					$174,458.70		$25.76
Total Fee Offsets (4)							—
Net Fee Due							$25.76

 

(1)	In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.
(2)	Consists of 157,170 shares of the Registrant’s common stock, par value $0.01 per share (the “Common Stock”) that became available for issuance on January 1, 2024, pursuant to the Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan by operation of an automatic annual increase provision therein.
(3)	Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the Registrant’s Common Stock as reported on OTC Pink Marketplace on January 22, 2024.
(4)	The Registrant does not have any fee offsets.

 

 

---